PharmacoEconomics

Health Utility Elicitation: Is There Still a Role for Direct Methods?
pp. 83-86(4)
Authors: Prosser, Lisa A.; Grosse, Scott D.; Wittenberg, Eve

Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer's Perspective
pp. 87-101(15)
Authors: Duran, Aurea; Sengupta, Nishan; Diamantopoulos, Alexander; Forster, Fiona; Kwong, Louis; Lees, Michael

Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer
pp. 103-118(16)
Authors: Griffiths, Robert I.; Barron, Richard L.; Gleeson, Michelle L.; Danese, Mark D.; O'Hagan, Anthony; Chia, Victoria M.; Legg, Jason C.; Lyman, Gary H.

Incorporating Calibrated Model Parameters into Sensitivity Analyses: Deterministic and Probabilistic Approaches
pp. 119-126(8)
Authors: Taylor, Douglas C.A.; Pawar, Vivek; Kruzikas, Denise T.; Gilmore, Kristen E.; Sanon, Myrlene; Weinstein, Milton C.

Why Not Real Economics?
pp. 127-131(5)
Author: Johnson, F. Reed

Real Economics Needs to Reflect Real Decisions: A Response to Johnson
pp. 133-136(4)
Authors: Sculpher, Mark; Claxton, Karl

Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery: A NICE Single Technology Appraisal
pp. 137-146(10)
Authors: Holmes, Michael; Carroll, Christopher; Papaioannou, Diana

Osteoporotic Fractures: A Systematic Review of US Healthcare Costs and Resource Utilization
pp. 147-170(24)
Authors: Budhia, Sangeeta; Mikyas, Yeshi; Tang, Michael; Badamgarav, Enkhe